<html xmlns:v="urn:schemas-microsoft-com:vml" xmlns:o="urn:schemas-microsoft-com:office:office" xmlns:w="urn:schemas-microsoft-com:office:word" xmlns:x="urn:schemas-microsoft-com:office:excel" xmlns:m="http://schemas.microsoft.com/office/2004/12/omml" xmlns="http://www.w3.org/TR/REC-html40">
<head>
<meta http-equiv="Content-Type" content="text/html; charset=us-ascii">
<meta name="Generator" content="Microsoft Word 14 (filtered medium)">
<!--[if !mso]><style>v\:* {behavior:url(#default#VML);}
o\:* {behavior:url(#default#VML);}
w\:* {behavior:url(#default#VML);}
.shape {behavior:url(#default#VML);}
</style><![endif]--><style><!--
/* Font Definitions */
@font-face
{font-family:Wingdings;
panose-1:5 0 0 0 0 0 0 0 0 0;}
@font-face
{font-family:SimSun;
panose-1:2 1 6 0 3 1 1 1 1 1;}
@font-face
{font-family:SimSun;
panose-1:2 1 6 0 3 1 1 1 1 1;}
@font-face
{font-family:Calibri;
panose-1:2 15 5 2 2 2 4 3 2 4;}
@font-face
{font-family:Tahoma;
panose-1:2 11 6 4 3 5 4 4 2 4;}
@font-face
{font-family:"Trebuchet MS";
panose-1:2 11 6 3 2 2 2 2 2 4;}
@font-face
{font-family:"\@SimSun";
panose-1:2 1 6 0 3 1 1 1 1 1;}
/* Style Definitions */
p.MsoNormal, li.MsoNormal, div.MsoNormal
{margin:0cm;
margin-bottom:.0001pt;
font-size:11.0pt;
font-family:"Calibri","sans-serif";}
h2
{mso-style-priority:9;
mso-style-link:"Heading 2 Char";
mso-margin-top-alt:auto;
margin-right:0cm;
mso-margin-bottom-alt:auto;
margin-left:0cm;
font-size:18.0pt;
font-family:"Times New Roman","serif";
font-weight:bold;}
a:link, span.MsoHyperlink
{mso-style-priority:99;
color:blue;
text-decoration:underline;}
a:visited, span.MsoHyperlinkFollowed
{mso-style-priority:99;
color:purple;
text-decoration:underline;}
p
{mso-style-priority:99;
mso-margin-top-alt:auto;
margin-right:0cm;
mso-margin-bottom-alt:auto;
margin-left:0cm;
font-size:12.0pt;
font-family:"Times New Roman","serif";}
p.MsoAcetate, li.MsoAcetate, div.MsoAcetate
{mso-style-priority:99;
mso-style-link:"Balloon Text Char";
margin:0cm;
margin-bottom:.0001pt;
font-size:8.0pt;
font-family:"Tahoma","sans-serif";}
span.Heading2Char
{mso-style-name:"Heading 2 Char";
mso-style-priority:9;
mso-style-link:"Heading 2";
font-family:"Times New Roman","serif";
font-weight:bold;}
span.BalloonTextChar
{mso-style-name:"Balloon Text Char";
mso-style-priority:99;
mso-style-link:"Balloon Text";
font-family:"Tahoma","sans-serif";}
span.EmailStyle21
{mso-style-type:personal;
font-family:"Trebuchet MS","sans-serif";
color:windowtext;}
span.EmailStyle22
{mso-style-type:personal-reply;
font-family:"Trebuchet MS","sans-serif";
color:#1F497D;}
.MsoChpDefault
{mso-style-type:export-only;
font-size:10.0pt;}
@page WordSection1
{size:612.0pt 792.0pt;
margin:72.0pt 72.0pt 72.0pt 72.0pt;}
div.WordSection1
{page:WordSection1;}
--></style><!--[if gte mso 9]><xml>
<o:shapedefaults v:ext="edit" spidmax="1029" />
</xml><![endif]--><!--[if gte mso 9]><xml>
<o:shapelayout v:ext="edit">
<o:idmap v:ext="edit" data="1" />
</o:shapelayout></xml><![endif]-->
</head>
<body lang="EN-US" link="blue" vlink="purple">
<div class="WordSection1">
<p class="MsoNormal" style="margin-bottom:12.0pt;background:white"><span style="font-size:9.5pt;font-family:"Arial","sans-serif";color:#333333">Please be invited to participate in NBC-16 – a broad Biotech event in The Netherlands.<o:p></o:p></span></p>
<p class="MsoNormal" style="margin-bottom:3.0pt;background:white"><span style="font-size:13.5pt;font-family:"Arial","sans-serif";color:#00575E">NBC-16 "Next Level Biotechnology"<o:p></o:p></span></p>
<p class="MsoNormal" style="line-height:14.6pt;background:white"><span style="font-size:9.5pt;font-family:"Arial","sans-serif";color:#333333">On the 14th of April 2016 NBV organizes the 16th edition of the Netherlands Biotechnology Conference (NBC-16).<o:p></o:p></span></p>
<p class="MsoNormal" style="margin-bottom:8.0pt;line-height:14.6pt;background:white">
<span style="font-size:9.5pt;font-family:"Arial","sans-serif";color:#333333">NBC-16 "Next Level Biotechnology" will highlight some of the most promising developments in biotechnology. Scientists working at universities and research institutes are performing
cutting edge science on biological systems and processes. Biotech entrepreneurs use this know how to develop all kinds of innovative products with immense economical and societal impacts.<o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:9.5pt;font-family:"Arial","sans-serif";color:#333333"><o:p> </o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:9.5pt;font-family:"Arial","sans-serif";color:#333333">Please consider sending in an abstract for poster and/or talk!<o:p></o:p></span></b></p>
<p class="MsoNormal"><b><span style="font-size:10.0pt;font-family:"Trebuchet MS","sans-serif";color:#1F497D"><o:p> </o:p></span></b></p>
<p class="MsoNormal"><span style="font-family:Wingdings">o</span> Cell and Fermentation Biotechnology<o:p></o:p></p>
<p class="MsoNormal"><span style="font-family:Wingdings">o</span> Green Biotechnology<o:p></o:p></p>
<p class="MsoNormal"><span style="font-family:Wingdings">o</span> Societal Aspects<o:p></o:p></p>
<p class="MsoNormal"><span style="font-family:Wingdings">o</span> Microbial Systems Biology & Synthetic Biology<o:p></o:p></p>
<p class="MsoNormal"><span style="font-family:Wingdings">o</span> Microbial Physiology<o:p></o:p></p>
<p class="MsoNormal"><span style="font-family:Wingdings">o</span> Product Isolation & Purification<o:p></o:p></p>
<p class="MsoNormal"><span style="font-family:Wingdings">o</span> Applied Biocatalysis<o:p></o:p></p>
<p class="MsoNormal"><span style="font-size:10.0pt;font-family:"Trebuchet MS","sans-serif""><o:p> </o:p></span></p>
<p class="MsoNormal"><span style="font-size:10.0pt;font-family:"Trebuchet MS","sans-serif""><a href="http://nbv.kncv.nl/nbc-16-biotechnology-the-next-level/speakers.184255.lynkx">http://nbv.kncv.nl/nbc-16-biotechnology-the-next-level/speakers.184255.lynkx</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:10.0pt;font-family:"Trebuchet MS","sans-serif";color:#1F497D"><o:p> </o:p></span></p>
<h2 style="mso-margin-top-alt:0cm;margin-right:0cm;margin-bottom:3.0pt;margin-left:0cm;background:white">
<span lang="NL" style="font-size:13.5pt;font-family:"Arial","sans-serif";color:#00575E;font-weight:normal">Keynotes<o:p></o:p></span></h2>
<p style="margin:0cm;margin-bottom:.0001pt;line-height:14.6pt;background:white"><span lang="NL" style="font-size:9.5pt;font-family:"Arial","sans-serif";color:#333333"> <o:p></o:p></span></p>
<p style="margin:0cm;margin-bottom:.0001pt;line-height:14.6pt;background:white"><strong><span lang="NL" style="font-size:9.5pt;font-family:"Arial","sans-serif";color:#333333;border:none windowtext 1.0pt;padding:0cm">John van der Oost</span></strong><span lang="NL" style="font-size:9.5pt;font-family:"Arial","sans-serif";color:#333333"><br>
<br>
<o:p></o:p></span></p>
<p style="margin:0cm;margin-bottom:.0001pt;line-height:14.6pt;background:white"><span lang="NL" style="font-size:9.5pt;font-family:"Arial","sans-serif";color:#333333">John van der Oost (1958) is molecular microbiologist/biochemist.
</span><span style="font-size:9.5pt;font-family:"Arial","sans-serif";color:#333333">He is group leader of Bacterial Genetics group at Wageningen University since 1995, currently consisting of 20 scientists, and on average 10 MSc students. He is (co-)author
of >250 scientific publications, with an H-factor >50. John is (co-) inventor of 13 patents. He has obtained an EMBO long-term fellowship, an EMBL fellowship, a KNAW fellowship, and is laureate of a NWO-VICI grant, and a NWO TOP grant. He has been coordinator
of two European networks. He participated in 3 STW projects. In 2005 John was appointed Full Professor, and in 2013 he was elected as EMBO member. Apart from metabolic engineering and synthetic biology projects, he works on CRISPR-Cas since 2005.<o:p></o:p></span></p>
<p style="margin:0cm;margin-bottom:.0001pt;line-height:14.6pt;background:white"><span style="font-size:9.5pt;font-family:"Arial","sans-serif";color:#333333"> <o:p></o:p></span></p>
<p style="margin:0cm;margin-bottom:.0001pt;line-height:14.6pt;background:white"><strong><span style="font-size:9.5pt;font-family:"Arial","sans-serif";color:#333333;border:none windowtext 1.0pt;padding:0cm">Alex Patist</span></strong><span style="font-size:9.5pt;font-family:"Arial","sans-serif";color:#333333"><o:p></o:p></span></p>
<p style="margin:0cm;margin-bottom:.0001pt;line-height:14.6pt;background:white"><span style="font-size:9.5pt;font-family:"Arial","sans-serif";color:#333333"> <o:p></o:p></span></p>
<p style="margin:0cm;margin-bottom:.0001pt;line-height:14.6pt;background:white"><span style="font-size:9.5pt;font-family:"Arial","sans-serif";color:#333333">Alex has over 15 years of experience in directing new product, process technology & optimization and
scale-up in the food, nutraceutical, biochemical & biofuel industries. Since 2013, he has been at Genomatica, a leading biotech innovator for the chemical industry. At Genomatica, he has led several teams responsible for technology transfer to customers worldwide;
development of high precision scale-up/scale-down methodologies; and selection and preparation of tolling facilities. In addition, he has been a catalyst in ‘mainstreaming’ a whole-process approach to deliver advantaged bioprocesses. A multi-cultural heritage
- and perhaps a Dutch sense of humor - help him bring together project teams across different countries, languages, core capabilities, company sizes and time zones. Previously, Alex was at Cargill R&D in Minneapolis, MN. During his tenure as Director of Technology,
he worked with major partners such as PepsiCo, Kraft and Nestle, taking ideas from concept, through patents, to rollout in areas such as natural sweeteners (e.g., Stevia) and improved line operations. Alex has a BS from Hogeschool Utrecht, MS from TU Eindhoven
and a Ph.D. from the University of Florida, all in Chemical Engineering.<o:p></o:p></span></p>
<p style="margin:0cm;margin-bottom:.0001pt;line-height:14.6pt;background:white"><span style="font-size:9.5pt;font-family:"Arial","sans-serif";color:#333333"> <o:p></o:p></span></p>
<p style="margin:0cm;margin-bottom:.0001pt;line-height:14.6pt;background:white"><strong><span style="font-size:9.5pt;font-family:"Arial","sans-serif";color:#333333;border:none windowtext 1.0pt;padding:0cm">Marc Robillard</span></strong><span style="font-size:9.5pt;font-family:"Arial","sans-serif";color:#333333"><o:p></o:p></span></p>
<p style="margin:0cm;margin-bottom:.0001pt;line-height:14.6pt;background:white"><span style="font-size:9.5pt;font-family:"Arial","sans-serif";color:#333333"> <o:p></o:p></span></p>
<p style="margin:0cm;margin-bottom:.0001pt;line-height:14.6pt;background:white"><span style="font-size:9.5pt;font-family:"Arial","sans-serif";color:#333333">Dr. Robillard initiated and led the team working on Tagworks’ In Vivo Chemistry within Philips Research
from 2006 until the spinout end of 2011. In 2003, he joined Philips Research to define and initiate their molecular medicine program in conjunction with the building of the corresponding laboratory facilities. As senior scientist and project leader he was
involved in several imaging and drug delivery projects before creating the In Vivo Chemistry technology. Prior to Philips he worked at Kreatech Diagnostics on the development of a portfolio of probes for drug targeting and microarray-based detection of DNA,
RNA and proteins. In addition he was a visiting scientist at the School of Biotechnology and Biomolecular Sciences, University of New South Wales, Sydney, and he worked at the CRO Syncom as a synthetic chemist. Dr. Robillard obtained his MSc and PhD in bio(in)organic
chemistry at, respectively, the University of Groningen and the Leiden Institute of Chemistry, The Netherlands. He has published 19 peer-reviewed papers and is a co-inventor on 18 patents.<o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:10.0pt;font-family:"Trebuchet MS","sans-serif";color:#1F497D"><o:p> </o:p></span></p>
<p class="MsoNormal"><span style="font-size:10.0pt;font-family:"Trebuchet MS","sans-serif""><br>
</span><span style="font-family:"Trebuchet MS","sans-serif";color:#008FD5"><br>
<br>
</span><span style="font-size:8.5pt;font-family:"Trebuchet MS","sans-serif";color:#008FD5">Hans Roubos | Principal Scientist Bioinformatics & Modeling | DSM Food Specialties B.V. | Alexander Fleminglaan 1 | 2613 AX Delft | Netherlands | T +31 (0)15 2792147
| Trade Register Number 27235314 | Stay connected: </span><a href="https://twitter.com/DSM"><span style="font-size:8.5pt;font-family:"Trebuchet MS","sans-serif";text-decoration:none"><img border="0" width="16" height="16" id="_x0000_i1030" src="cid:image001.png@01D16B16.49B44AE0" alt="http://static.dsm.com/content/dam/dsm/images/twitter.png"></span></a><span style="font-size:8.5pt;font-family:"Trebuchet MS","sans-serif";color:#008FD5"> </span><a href="https://www.linkedin.com/company/3108"><span style="font-size:8.5pt;font-family:"Trebuchet MS","sans-serif";text-decoration:none"><img border="0" width="16" height="16" id="_x0000_i1029" src="cid:image002.png@01D16B16.49B44AE0" alt="http://static.dsm.com/content/dam/dsm/images/linkedin.png"></span></a><span style="font-size:8.5pt;font-family:"Trebuchet MS","sans-serif";color:#008FD5"> </span><a href="https://www.youtube.com/user/dsmcompany"><span style="font-size:8.5pt;font-family:"Trebuchet MS","sans-serif";text-decoration:none"><img border="0" width="16" height="16" id="_x0000_i1028" src="cid:image003.png@01D16B16.49B44AE0" alt="http://static.dsm.com/content/dam/dsm/images/youtube.png"></span></a><span style="font-size:8.5pt;font-family:"Trebuchet MS","sans-serif";color:#008FD5"> </span><a href="https://plus.google.com/117689312065000346895#117689312065000346895/posts"><span style="font-size:8.5pt;font-family:"Trebuchet MS","sans-serif";text-decoration:none"><img border="0" width="16" height="16" id="_x0000_i1027" src="cid:image004.png@01D16B16.49B44AE0" alt="http://static.dsm.com/content/dam/dsm/images/googleplus.png"></span></a><span style="font-size:8.5pt;font-family:"Trebuchet MS","sans-serif";color:#008FD5"> </span><a href="https://www.facebook.com/DSMcompany"><span style="font-size:8.5pt;font-family:"Trebuchet MS","sans-serif";text-decoration:none"><img border="0" width="16" height="16" id="_x0000_i1026" src="cid:image005.png@01D16B16.49B44AE0" alt="http://static.dsm.com/content/dam/dsm/images/facebook.png"></span></a><span style="font-size:8.5pt;font-family:"Trebuchet MS","sans-serif";color:#008FD5"><br>
<br>
</span><span style="font-family:"Trebuchet MS","sans-serif";color:#008FD5"><img border="0" width="200" height="66" id="_x0000_i1025" src="cid:image006.jpg@01D16B16.49B44AE0" alt="http://static.dsm.com/content/dam/dsm/images/DSM_Email_EN.jpg"></span><span style="font-family:"Times New Roman","serif""><o:p></o:p></span></p>
<p class="MsoNormal"><o:p> </o:p></p>
</div>
<br>
<hr>
<font face="Arial" color="Gray" size="1"><br>
DISCLAIMER:<br>
This e-mail is for the intended recipient only.<br>
If you have received it by mistake please let us know by reply and then delete it from your system; access, disclosure, copying, distribution or reliance on any of it by anyone else is prohibited.<br>
If you as intended recipient have received this e-mail incorrectly, please notify the sender (via e-mail) immediately.<br>
</font>
</body>
</html>